ReviewJournal of neuro-oncology2014
Management of medically refractory prolactinoma.
Review in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Pooled it
- Long-term endocrine outcomes of transsphenoidal surgery for prolactinomas: a 20-year single-center cohort study.Pituitary · 2026Article
- p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas.Redox biology · 2026Article
- Aggressive prolactinomas in men are associated with visual disturbances and pituitary hormone deficiencies.Scientific reports · 2025Article
- Risk-Stratifying Pituitary Adenoma Treatment: A Cohort Analysis and Risk Prediction of Hypopituitarism.Journal of clinical medicine · 2025Article
- Endoscopic endonasal transcavernous surgery for a contemporary series of 59 prolactinomas.Pituitary · 2025Article
- The Changing Treatment Paradigm for Prolactinoma-A Prospective Series of 100 Consecutive Neurosurgical Cases.The Journal of clinical endocrinology and metabolism · 2025Article
- A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies.Journal of clinical medicine · 2025Review
- Artificial intelligence-driven approaches in pituitary neuroendocrine tumors: integrating endocrine-metabolic profiling for enhanced diagnostics and therapeutics.Frontiers in endocrinology · 2025Review
- Article
- The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2.International journal of molecular sciences · 2024Article
- Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.Journal of endocrinological investigation · 2024Review
- Stereotactic Radiosurgery Outcomes in Medically and Surgically Failed or Nonsurgical Candidates with Medically Failed Prolactinomas: A Systematic Review and Meta-Analysis.Journal of neurological surgery. Part B, Skull base · 2023Article
- Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.The Journal of clinical endocrinology and metabolism · 2023Article
- Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?Pituitary · 2023Observational
- Refractory lactotroph adenomas.Pituitary · 2023Review
- Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need.Pituitary · 2023Review
- Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.Molecular neurobiology · 2023Article
- Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.Journal of medical case reports · 2023Review
- The Role of Aromatase Inhibitors in Male Prolactinoma.Journal of clinical medicine · 2023Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to dopamine agonists is defined here as failure to normalize prolactin levels and failure to decrease macroprolactinoma size by ≥50 %. Failure to normalize prolactin levels is found in about 25 % of patients treated with bromocriptine and 10-15 % of those treated with cabergoline. Failure to achieve at least a 50 % reduction in tumor size occurs in about one-third of those treated with bromocriptine and 10-15 % of those treated with cabergoline. Treatment approaches for patients resistant to dopamine agonists include changing to another dopamine agonist and increasing the dose of the drug as long as there is continued response to the dose increases and no adverse effects with higher doses. Transsphenoidal surgery is also an option. Clomiphene, gonadotropins, and GnRH can be used if fertility is desired. For those not desiring fertility, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. In many patients modest or even no reduction in tumor size may be acceptable as long as there is not tumor growth. Hormone replacement [estrogen or testosterone] may cause a decrease in efficacy of the dopamine agonist. Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches. Temozolomide may be useful as a last resort for aggressive, invasive tumors refractory to other medical and ablative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.